SCHEMBL4421900

SCHEMBL4421900

O=S(=O)(c1ccc(Oc2ccccn2)cc1)N1CC2C([CH]c3ccc(N4CCOCC4)c(F)c3)C2C1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 1/20 0.38
POLB P06746 2/20 0.37
ALDH1A1 P00352 5/20 0.37
MAPK1 P28482 4/20 0.37
MEN1 O00255 1/20 0.37
MMP1 P03956 1/20 0.37
MMP13 P45452 1/20 0.37
KDM1A O60341 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TSHR P16473 3/20 0.36
HTT P42858 1/20 0.36
USP2 O75604 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4431014 0.88 LMNA (0.43) LMNASMN1; SMN2KMT2AGAAPOLB
SCHEMBL4418783 0.86 KMT2A (0.42) LMNASMN1; SMN2KMT2AGAAPOLB
SCHEMBL4424440 0.83 HSD11B1 (0.41) LMNASMN1; SMN2KMT2AGAAMEN1
SCHEMBL4415660 0.83 ALDH1A1 (0.40) LMNASMN1; SMN2KMT2AGAAALDH1A1
SCHEMBL4415659 0.82 HTT (0.43) LMNASMN1; SMN2KMT2AGAAALDH1A1
SCHEMBL4421354 0.80 SLC6A9 (0.43) LMNASMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL2168711 0.76 KMT2A (0.38) LMNAKMT2AGAAPOLBALDH1A1
SCHEMBL4420883 0.75 LMNA (0.45) LMNASMN1; SMN2GAAALDH1A1
SCHEMBL4430192 0.72 MCOLN3 (0.44) LMNASMN1; SMN2KMT2AGAAPOLB
SCHEMBL4425059 0.71 KMT2A (0.49) LMNASMN1; SMN2KMT2AGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 LMNA 4565/4885SMN1; SMN2 4003/4885KMT2A 1892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.